



For **reauthorization**:

1. Member has a growth rate of at least 2 cm/year; AND

2. (X-ray results must be included).

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Skytrofa (lonapegsomatropin)

